Ajinomoto service is a company that provides a number of active pharmaceutical products to the pharmaceutical industry along with its joint venture company, Granules India Limited.
The company press states that this joint venture was actually created in 2011 by S.A Ajinomoto OmniChem N.V. Both the companies worked with each other to produce small molecule intermediates and API manufacturing to the pharmaceutical industry. Ajinomoto Bio-Pharma Services has recently announced on 29 August 2019 that it is going to buy rest of the 50 percent ownership interest-based in Visakhapatnam, India, Granules OmniChem private limited (GOC) from its joint venture partner who is Granules India Limited.
Financial terms of the acquisition were not disclosed; the last date of the transaction is expected during the fourth quarter of 2019.
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services provides biopharmaceutical contract development and manufacturing services, and it is a completely integrated contract development and manufacturing organization with different sites in Belgium, Japan, India, and the U.S.
It provides a broad range of new and totally fresh facilities and capabilities to pre-clinical and pilot programs to a commercial level. It includes not only corynex protein expression technology but also oligonucleotide synthesis, antibody-drug conjugation, high potency active pharmaceutical ingredients, biocatalysis, and more.
Consolidating CDMO Networks
According to David Enloe, CEO of Ajinomoto Bio-Pharma services, the investment is a powerful follow up that boosts the past efforts of the overall Ajinomoto group to merge the contract service that was offered in the pharmaceutical industry.
During October, in 2018, there was a large molecule manufacturer, who also provided fill finish services, asked Ajinomoto OmniChem to join them and become partners, who were a small molecule manufacturer at that time. So they both made a deal and joined their business to form a company which is famous as Ajinomoto Bio Pharma services.
By bringing the contract development and manufacturer organization business together, Ajinomoto planned to open the way for more range of services in multiple production platforms for the clients to strengthen their commitments by offering a number of CDMO offers.
Last year, Ajinomoto Bio-Pharma gained in $100 million investment to expand the facilities in San Diego, US, and Belgium.
According to K.V.V Raju, who is the CEO of Granules OmniChem, they are very happy and contented to know that they are fully joined a member of Ajinomoto BioPharma. He further adds that, as he is an official part of contract development and manufacturing organization, so his team can bring betterment and improve the Ajinomoto’s ability to deliver value so they can develop trust in their customer’s heart and proudly take part in making improvements and contribute in the health of humanity.
Ajinomoto Bio-Pharma is a service that focuses on the continuous flow of manufacturing, providing high-quality products and ingredients to satisfy their client’s needs.